

Please amend this application as follows:

I. Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-8. (Cancelled).

9. (Currently Amended) A method of treating a condition which can be alleviated by an EP₂ receptor agonist, which method comprises administering to a patient in need of treatment an effective amount of (trans-2-[4-(1-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid, of which at least 80% by weight is selected from one of the following forms:

(1R,2S)-2-[4-(1-(R)-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid or a pharmaceutically acceptable salt thereof; or

(1R,2S)-2-[4-(1-(S)-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid or a pharmaceutically acceptable salt thereof.

10. (Withdrawn) The method according to claim 9, wherein the condition alleviated by agonism of an EP₂ receptor is selected from the group consisting of: glaucoma, dysmenorrhoea and pre-term labour.

Claims 11-15. (Cancelled).

16. (Withdrawn) The method according to claim 9 wherein the condition is psoriasis.

17. (Previously Presented) The method according to claim 9 wherein the condition is an inflammatory lung disease.

Claim 18. (Cancelled).

19. (Previously Presented) The method of claim 9 wherein the condition is selected from a group consisting of psoriasis, dysmenorrhoea, pre-term labour, glaucoma, osteoporosis, asthma, allergy, bone disease, fracture repair, infertility, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer and renal disease.

20. (Previously Presented) The method of claim 19 wherein the condition is selected from a group consisting of psoriasis, pre-term labour, glaucoma, and an inflammatory lung disease; and the EP₂ receptor agonist is (1R,2S)-2-[4-(1-(S)-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid or a pharmaceutically acceptable salt thereof.

21. (Previously Presented) The method of claim 19 wherein the condition is selected from a group consisting of psoriasis, dysmenorrhoea, pre-term labour, glaucoma, and an inflammatory lung disease; and the EP₂ receptor agonist is (1R,2S)-2-[4-(1-(R)-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid or a pharmaceutically acceptable salt thereof.

22. (New) A method of treating a condition which can be alleviated by an EP₂ receptor agonist, which method comprises administering to a patient in need of treatment an effective amount of a compound that is substantially pure:

(1R,2S)-2-[4-(1-(R)-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid or a pharmaceutically acceptable salt thereof; or

(1R,2S)-2-[4-(1-(S)-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid or a pharmaceutically acceptable salt thereof.

23. (New and Withdrawn) The method according to claim 22, wherein the condition alleviated by agonism of an EP₂ receptor is selected from the group consisting of: glaucoma, dysmenorrhoea and pre-term labour.

24. (New and Withdrawn) The method according to claim 22 wherein the condition is psoriasis.

25. (New) The method according to claim 22 wherein the condition is an inflammatory lung disease.

26. (New) The method of claim 22 wherein the condition is selected from a group consisting of psoriasis, dysmenorrhoea, pre-term labour, glaucoma, osteoporosis, asthma, allergy, bone disease, fracture repair, infertility, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer and renal disease.

27. (New) The method of claim 26 wherein the condition is selected from a group consisting of psoriasis, pre-term labour, glaucoma, and an inflammatory lung disease; and the EP₂ receptor agonist is (1R,2S)-2-[4-(1-(S)-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid or a pharmaceutically acceptable salt thereof.

28. (New) The method of claim 26 wherein the condition is selected from a group consisting of psoriasis, dysmenorrhoea, pre-term labour, glaucoma, and an inflammatory lung

disease; and the EP₂ receptor agonist is (1R,2S)-2-[4-(1-(R)-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid or a pharmaceutically acceptable salt thereof.